Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

From the original abstract

Authors’ conclusion — excerpt

“In adults with overweight or obesity without diabetes, next generation incretin based treatments achieved greater weight loss than conventional GLP-1 receptor agonists.”

From the abstract’s conclusions section. This is a short quotation from the authors, not a full study appraisal.

Read the full abstract & conclusion

How to read this paper

This paper brings together existing research. Its conclusions depend on the included studies and their methods; it is not a separate treatment trial.

A brief excerpt cannot capture the complete methods, results, adverse events, or limitations. Check the full abstract and original paper before interpreting the finding.

Publication & source

Why this paper is included: A network meta-analysis includes retatrutide trial estimates for weight loss and treatment discontinuation.
Publication indexing: Journal Article
Source checked: October 4, 2026. Years follow journal issues; online-first dates may differ.

Open PubMed record PMID 42688617 · Journal and full-text links

Educational research information. A publication does not verify the identity, quality, or safety of products sold here.

Back to Retatrutide studies